

**Chiron's Chairman Adopts Rule 10b5-1 Trading Plan**

EMERYVILLE, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that Sean P. Lance, chairman of Chiron's board of directors, has adopted a pre-arranged trading plan in accordance with Securities and Exchange Commission Rule 10b5-1. The plan permits Mr. Lance to diversify his investment portfolio in an orderly and pre-arranged manner in anticipation of his announced retirement in May 2004.

Under the plan, Mr. Lance will exercise a substantial portion of his vested stock options and will execute a series of daily sales of the Chiron stock acquired by exercising these options. The plan covers an aggregate of 1,286,797 shares, including 750,000 shares covered by options that must be exercised within 90 days of his retirement that were granted upon the initial hiring of Mr. Lance to serve as Chiron's president and chief executive officer. Shares are expected to be sold on a daily basis commencing on November 2, 2003, at the rate of approximately 9,000 shares per day, subject to predetermined limit prices.

Rule 10b5-1 of the Securities Exchange Act of 1934 allows insiders to adopt written plans for trading securities in a non-discretionary, pre-scheduled manner in order to avoid concerns about initiating stock transactions when the insider may be aware of non-public information. Such plans also allow insiders to diversify their holdings and to minimize the market effect of stock sales by spreading them out over time.

**About Chiron**

Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. The company has a strategic focus on cancer and infectious disease. Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. The company commercializes its products through three business units: BioPharmaceuticals, Vaccines and Blood Testing. For more information about Chiron, visit the company's website at [www.chiron.com](http://www.chiron.com).

This news release contains forward-looking statements that involve risks and uncertainties and are subject to change. A full discussion of the company's operations and financial condition, including factors that may affect its business and future prospects, is contained in documents the company has filed with the SEC, including the form 10-Q for the quarter ended June 30, 2003, and the form 10-K for the year ended December 31, 2002, and will be contained in all subsequent periodic filings made with the SEC.

Consistent with SEC Regulation FD, we do not undertake an obligation to update the forward-looking information we are giving today.

SOURCE Chiron Corporation